|
Heart Attack | Myocardial Infarction Studies
The studies below discuss heart attack or Myocardial Infarction (MI) studies.
Samir Damani, Andrea Bacconi, Ondrej Libiger, Aparajita H. Chourasia, Rod Serry, Raghava Gollapudi,RonGoldberg, Kevin Rapeport, Sharon Haaser, Sarah Topol, Sharen Knowlton, Kelly Bethel,Peter Kuhn, Malcolm Wood, Bridget Carragher, Nicholas J. Schork, John Jiang, Chandra Rao,Mark Connelly, Velia M. Fowler, and Eric J. Topol
Sci Transl Med 21 March 2012 4:126ra33. [DOI:10.1126/scitranslmed.3003451] |
-
Treating heart attack patients with regenerative stem cells obtained from their own fat deposits may be feasible and safe, according to a small, first-of-its-kind study.
-
Heart muscle damage in stem cell-treated patients decreased more than half after six months; placebo-treated patients showed no change.
-
Stem cell recipients had a greater increase in heart function, but the difference was not considered significant.
|
Berton G, Cordiano R, Cavuto F, Giacomini G, De Toni R, Palatini P.
Department of Cardiology, Conegliano General Hospital, Conegliano, Italy.
Am J Cardiol. 2012 Jan 3. [Epub ahead of print] |
Nikolsky E, Mehran R, Dangas GD, Yu J, Parise H, Xu K, Pocock SJ, Stone GW.
Rambam Health Care Campus and Technion Israel Institute of Technology, Haifa, Israel; Cardiovascular Research Foundation, New York, New York.
Am J Cardiol. 2011 Dec 21. [Epub ahead of print] |
Eur Heart J first published online January 11, 2012 doi:10.1093/eurheartj/ehr432
2012 doi:10.1093/eurheartj/ehr432
Claes Held, Romaina Iqbal, Scott A. Lear, Annika Rosengren, Shofiqul Islam,James Mathew, and Salim Yusuf |
Anja M. van der Laan, Alexander Hirsch, Lourens F.H.J. Robbers, Robin Nijveldt, Ingrid Lommerse, Ronak Delewi, Pieter A. van der Vleuten, Bart J. Biemond, Jaap Jan Zwaginga, Wim J. van der Giessen, Felix Zijlstra, Albert C. van Rossum, Carlijn Voermans, C. Ellen van der Schoot, Jan J. Piek
American Heart Journal - January 2012 (Vol. 163, Issue 1, Pages 57-65.e2,
DOI: 10.1016/j.ahj.2011.09.002) |
|
|
|
The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse
Eleonora Mezzaroma, Stefano Toldo, Daniela Farkas, Ignacio M. Seropian,
Benjamin W. Van Tassell, Fadi N. Salloum, Harsha R. Kannan, Angela C. Menna, Norbert F. Voelkel, and Antonio Abbate
PNAS 2011 ; published ahead of print November 21, 2011, doi:10.1073/pnas.1108586108 |
|
Efficacy of exercise-based cardiac rehabilitation post–myocardial infarction: A systematic review and meta-analysis of randomized controlled trials Patrick R. Lawler, Kristian B. Filion, Mark J. Eisenberg
American Heart Journal - 05 September 2011 (10.1016/j.ahj.2011.07.017) |
Salisbury AC, Reid KJ, Alexander KP, Masoudi FA, Lai SM, Chan PS, Bach RG, Wang TY, Spertus JA, Kosiborod M.
Arch Intern Med. 2011 Aug 8. |
Recovery From Hospital-Acquired Anemia After Acute Myocardial Infarction and Effect on Outcomes.
Salisbury AC, Kosiborod M, Amin AP, Reid KJ, Alexander KP,
Spertus JA, Masoudi FA.
Saint Luke's Mid America Heart Institute, Kansas City, Missouri; University of Missouri-Kansas City School of Medicine, Kansas City, Missouri.
Am J Cardiol. 2011 Jul 22 |
Diagnosing Acute Myocardial Infarction in Patients With Left Bundle Branch Block.
Lopes RD, Siha H, Fu Y, Mehta RH, Patel MR, Armstrong PW, Granger CB.
Am J Cardiol. 2011 Jul 2.
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina. |
Lee CW, Hwang I, Park CS, Lee H, Park DW, Kang SJ, Lee SW, Kim YH, Park SW, Park SJ.
Department of Medicine, Asan Medical Center, University of Ulsan, Seoul, Korea.
Am J Cardiol. 2011 Jul 2 |
|
JAMA: Administration of Erythropoietin to Patients With Heart Attack Who Undergo Coronary Intervention Procedures Does Not Reduce Size of Heart Muscle Involvement and is Associated With Higher Rates of Adverse Events
CHICAGO—Intravenous administration of epoetin alfa, a product that stimulates red blood cell production, to patients with heart attack who were undergoing percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), did not provide reduction in the size of the heart muscle involved and was associated with higher rates of adverse cardiovascular events, according to a study in the May 11 issue of JAMA |
|
Adam C. Salisbury, Paul S. Chan, Kensey L. Gosch, Donna M. Buchanan, John A. Spertus
American Journal of Cardiology - 15 April 2011 (Vol. 107, Issue 8, Pages 1105-1110, DOI: 10.1016/j.amjcard.2010.12.005) |
|
Regional prevention project involving 10,000 adults cuts heart attacks by 25 percent
The Heart of New Ulm Project, which is merging environmental, peer leadership and individual interventions across an entire rural Minnesota community with the assistance of a healthcare system, worksites and the general community to prevent coronary heart disease, has shown a 24 percent reduction in the number of acute heart attacks in a five-quarter period, compared with the previous five-quarter period of evaluation. |
|
Int Heart J. 2011;52(1):1-6.
Kim MC, Ahn Y, Cho KH, Lee MG, Ko JS, Park KH, Sim DS, Yoon NS, Yoon HJ, Kim KH, Hong YJ, Park HW, Kim JH, Jeong MH, Cho JG, Park JC, Kang JC.
Department of Cardiology, Cardiovascular Center, Clinical Trial Center, Chonnam National University Hospital. |
FDA Drug Safety Podcast for Healthcare Professionals: Safety Review update of Abacavir and possible increased risk of heart attack
(Podcast transcript)
Welcome, my name is Lindsay Davison, a pharmacist in the Division of Drug Information. On March 1, 2011, the Food and Drug Administration issued a Drug Safety Communication updating the public about its ongoing safety review of abacavir and a possible increased risk of heart attack. Abacavir is an antiviral medication used in combination with other antiretroviral drugs for the treatment of HIV-1 infection.
Available medications that contain abacavir include Ziagen, Trizivir, and Epzicom. |
Schwartz BG, Mayeda GS, Burstein S, Economides C, Kloner RA.
Therapeutic Endoscopy Gastroenterology and Hepatology Huntsman Cancer Center University of Utah, Salt Lake City, UT 84132, USA. |
|
Emerg Med J. 2010 Sep 8.
Adnet F, Renault R, Jabre P, Kulstad E, Galinski M, Lapostolle F.
SAMU 93 - EA 3409, Avicenne Hospital, Bobigny, France
|
J Cardiol. 2010 Aug 25.
Kim W, Cho JS, Hong YJ, Ahn Y, Jeong MH.
The Cardiology Division, Department of Internal Medicine, Kyung Hee University, Seoul, Republic of Korea.
|
Featured Angina| Acute Coronary Syndrome and Heart Disease Interviews
|
Highlights of Article by Dr. Erik Hess et of Mayo Clinic ;CIRCOUTCOMES 2012
|
-
Chest pain is the 2nd most common reason patients come to EDs across the United States
-
Initial testing – including information obtained from the history, physical exam, electrocardiogram, and cardiac troponin – identifies > 98% of heart attacks
-
To avoid missing a diagnosis of heart attack or pre-heart attack symptoms, emergency physicians often admit patients to observation units or to the hospital for extensive diagnostic testing, including stress testing
-
This results in false positive test results, unnecessary exposure to radiation, and unnecessary downstream procedures such as stent placement in arteries of the heart
-
Decision aids are evidence-based tools designed to educate and engage patients in decisions regarding their care
-
We hypothesized that patients who were educated regarding their future risk for a heart attack and engaged in the decision of whether to be admitted to the observation unit for stress testing or to follow-up with a Mayo Clinic heart doctor in the next 72 hours would have greater knowledge about their short-term risk for heart attack, be more aware of the management options, and choose less intensive approaches to evaluation
-
We randomly assigned 204 patients who came to the ED with chest pain and were being considered for observation unit admission to the decision aid or to usual care
-
Decision aid patients:
-
Had greater knowledge regarding their short-term risk for a heart attack
-
Less frequently decided to be admitted to the observation unit for stress testing
-
Had 4 times greater engagement in the decision making process
-
Had no adverse events within 30 days of the ED visit
-
Take home points
-
Patients want to be educated and engaged in decisions regarding their care
-
Once properly informed and engaged in treatment decisions, patients often choose less intensive treatment options
-
Integrated health systems like the Mayo Clinic in which physicians collaboratively work together to provide ER patients ready access to outpatient follow-up have potential to improve the value of Emergency care
|
|
|
|
Glucose, Insulin and Potassium (“GIK”) TO MINIMIZE IMPACT OF HEART ATTACKS BEFORE PATIENTS GET TO THE HOSPITAL
Study puts life-saving drugs in the hands of paramedics, decreasing rate of cardiac arrest and death from heart attacks
CHICAGO (March 27, 2012) — Paramedics can potentially reduce someone’s chances of having a cardiac arrest or dying by 50 percent by immediately administering a mixture of glucose, insulin and potassium (“GIK”) to people having a heart attack, according to research presented today at the American College of Cardiology’s 61st Annual Scientific Session. The Scientific Session, the premier cardiovascular medical meeting, brings cardiovascular professionals together to further advances in the field.
The study showed that patients who received GIK immediately after being diagnosed with acute coronary syndrome — which indicates a possible heart attack is either in progress or on the way — were 50 percent less likely to have cardiac arrest (a condition in which the heart suddenly stops beating) or die than those who received a placebo, although the treatment did not prevent the heart attack from occurring. The reduction in in-hospital cardiac arrest or death was a “secondary endpoint”, so statistically was not definitive, but was consistent with how GIK seems to work in experimental models of heart attack.
The effect was also present for patients with ST-elevation heart attacks, which require immediate treatment. For those patients, immediate GIK was associated with a 60 percent reduction in in-hospital cardiac arrest or death.
“When started immediately in the home or on the way to the hospital — even before the diagnosis is completely established — GIK appears not completely prevent any heart attack from occurring, but appeared in this trial to reduce the size of heart attacks and to reduce by half the risk of having a cardiac arrest or dying,” said Harry P. Selker, MD, MSPH, executive director of the Institute for Clinical Research and Health Policy Studies at Tufts Medical Center, who led the study with Joni Beshansky, RN, MPH, co-principal investigator and project director. “Acute coronary syndromes represent the largest cause of death in this country. GIK is a very inexpensive treatment that appears to have promise in reducing those deaths and morbidity.”
The cost of the treatment is about $50.
“Because the trial is the first to show GIK could be effective when used by paramedics in real-world community settings, it could have important implications for the treatment of heart attacks,” Dr. Selker said. Previous clinical trials have shown no consistent effect, likely because the GIK was given too late to help. This study, the “IMMEDIATE Trial,” was the first to test the effectiveness of administering GIK at the very first signs of a threatening heart attack, in the community, rather than waiting hours until the diagnosis was well-established at a hospital, as done in previous clinical trials.
“We wanted to do something that is effective and can be used anywhere,” said Dr. Selker. “We’ve done a lot of studies of acute cardiac care in emergency departments and hospitals, but more people die of heart attacks outside the hospital than inside the hospital. Hundreds of thousands of people per year are dying out in the community; we wanted to direct our attention to those patients.”
The researchers trained paramedics in 36 Emergency Medical Services systems in 13 cities across the country to administer GIK after determining that a patient was likely having a threatened or already established heart attack using electrocardiograph-based ACI-TIPI (acute cardiac ischemia time-insensitive predictive instrument) and thrombolytic predictive instrument decision support that prints patient-specific predictions on the top of an electrocardiogram. The paramedics used these predictions to decide if a patient would likely benefit from treatment. There were 911 patients randomized to receive either the GIK treatment or a placebo.
Administering GIK immediately also reduced the severity of the damage to the heart tissue from the heart attack. On average, 2 percent of the heart tissue was destroyed by the heart attack in people receiving GIK, compared with 10 percent in those who received the placebo. Although a significant proportion of suspected heart attacks are later determined to be false alarms (23 percent in this study), administering GIK does not appear to cause any harmful effects in such patients.
The research team will follow up with study participants at six and 12 months to evaluate the longer-term benefit of the GIK treatment.
This study was funded by the NIH’s National Heart, Lung and Blood Institute.
|
|
Keywords and tags:
Angina, atypical angina, heart disease,chest pain, angina pectoris, chest pains, cardiology ,ivabradine for chronic angina, emergency room evaluation of chest pain, heart attacks, cardiac syndrome X,cpr, heart disease in women, cholesterol, lipids, heart medications, aspirin, cardiologists, ekg, ecg, echocardiology, heart surgery, bypass surgery, stents, spiral CTs, 64 slice CTs, chest pain, heart risk factors, cardiology news, angina.com, CRP, C Reactive Protein, troponins, troponin I, troponin T, Prinzmetal's angina, nitrates, angina treatment, JUPITER study, Crestor, CHF, congestive heart failure, Avandia, myeloperoxidase, MPO, biomarkers, AEDs, cardiac defibrillators, cardiac CTs, coronary 64 slice scanners,128 slice CT, 256 Cat Scan, Vitamin D and heart disease, Get with the Program -Coronary Artery Disease updates, Acute Coronary Syndrome, stress tests, thallium stress test, PCI, angioplasty, CABG, coronary artery bypass surgery, calcium
Angina | Heart Disease Resourses
| Chest Pain
Amazon.com 's Editorial Reviews
Angina: New Ways to Treat
Chronic Chest Pain
Part of the award winning public television series Healthy head
/Healthy Mind. It's one of the scariest medical symptoms for people who are generally healthy: a tightening, painful feeling in the chest known as Angina. In some cases this chest pain can be a serious warning that requires immediate treatment. But for the millions of people with chronic, stable angina the discomfort is something that can be readily managed with a variety of treatments. In this program we take a look at what generally causes angina, what can be done to prevent it and how it can be effectively treated with lifestyle changes, innovative drug therapies and medical procedures.
|
Amazon.com Editorial Review:
Philips HeartStart Home Defibrillator (AED)
Be prepared for the unexpected.
When sudden cardiac arrest (SCA) strikes, the electrical system of the heart short circuits, causing the heart to quiver rather than pump in a normal rhythm. It typically results in the abnormal heart rhythm know as ventricular fibrillation (VF). It usually happens without warning and the majority of people have no previously recognized symptoms of heart disease. And it most often happens at home. For the best chance of survival from SCA caused by VF, a defibrillator should be used within 5 minutes. Yet, less than 1 in 20 people survive largely because a defibrillator does not arrive in time.
Just as seat belts or airbags do not save every life in a traffic accident, a defibrillator will not save every person who suffers a sudden cardiac arrest. Yet many lives could be saved if more people could be reached more quickly.
|
|
Angina.com Tag Cloud | Angina Keywords
|
**************************************
|
